Comparative Pharmacology
Head-to-head clinical analysis: DOCIVYX versus FORTAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOCIVYX versus FORTAZ.
DOCIVYX vs FORTAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Docivyx is a docetaxel formulation; it binds to tubulin, promoting assembly of microtubules and inhibiting depolymerization, leading to cell cycle arrest and apoptosis.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, leading to cell lysis.
75 mg/m2 intravenously over 1 hour every 3 weeks.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day for serious infections.
None Documented
None Documented
Terminal elimination half-life is 24-48 hours; prolonged with hepatic impairment.
2 hours (normal renal function); prolonged to 12-20 hours in ESRD
Primarily hepatic metabolism followed by biliary excretion; <10% excreted unchanged in urine.
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; 5-10% biliary/fecal
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic